Strauss, 72,147 patient budesonide prophylaxis study: 24% lower mortality [p=0.01], 22% lower ICU admission [p=0.003], and 19% lower hospitalization [p<0.0001] https://c19p.org/strauss
copied to clipboard
Intranasal Corticosteroids Are Associated with Better Outcomes in Coronavirus Disease 2019
et al., The Journal of Allergy and Clinical Immunology: In Practice, doi:10.1016/j.jaip.2021.08.007
Retrospective 72,147 COVID-19+ patients in the USA, showing lower mortality, ICU admission, and hospitalization with intranasal corticosteroid use.
|
risk of death, 23.5% lower, RR 0.76, p = 0.01, treatment 231 of 10,187 (2.3%), control 1,649 of 61,960 (2.7%), NNT 254, adjusted per study, odds ratio converted to relative risk, PSM.
|
|
risk of ICU admission, 22.3% lower, RR 0.78, p = 0.003, treatment 376 of 10,187 (3.7%), control 2,559 of 61,960 (4.1%), adjusted per study, odds ratio converted to relative risk, PSM.
|
|
risk of hospitalization, 18.9% lower, RR 0.81, p < 0.001, treatment 1,676 of 10,187 (16.5%), control 10,932 of 61,960 (17.6%), adjusted per study, odds ratio converted to relative risk, PSM.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Strauss et al., 8/23/2021, retrospective, USA, North America, peer-reviewed, 8 authors, study period 1 April, 2020 - 31 March, 2021.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.